Anti-cancer combination therapy including CTLA-4 blocker and PD-1 blocker

摘要

Disclosed is an anti-cancer combination therapy containing a CTLA-4 blocker and a PD-1 blocker. In particular, the CTLA-4 blocker is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment, and the PD-1 blocker is an anti-PD-1 antibody or anti-PD-L1 antibody or the like thereof. A combination therapy that is an antibody fragment is disclosed. [Selection diagram] FIG. 11